Static Chart Nanobiotix

Equities

Market Closed - Euronext Paris Other stock markets 11:35:00 2024-05-17 am EDT			5-day change	1st Jan Change
6.765 ^EUR	-0.37%		+6.20%	+1.88%

May. 14	Nanobiotix to Proceed to Phase 2 Trial of Lung Cancer Treatment	MT
May. 14	Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer	CI

Duration

Period